New meds are encroaching on a corner of the market for Novartis’ broader severe asthma treatment Xolair. But in response, the company is making it easier to…

Pfizer CEO Ian Read has been dropping hints like bread crumbs, and now it's official: The company has decided not to split up. Cue the wailing from…

Amgen’s Humira biosimilar is now officially FDA-approved. It has an official brand name, Amjevita. But that doesn’t mean it will come to a pharmacy near you…

Vanda is a small drugmaker. Its two central nervous system drugs generated only about $100 million in sales last year. But with lots of M&A dollars being…

Thirty-five U.S. states and the District of Columbia have filed suit against the U.K.'s Indivior, alleging anticompetitive actions for the opioid Suboxone…

Endo has struggled lately to right the ship, and now it’s giving a new skipper a turn at the wheel.

UnitedHealth dropped the latest formulary bomb Wednesday with a proposal to exclude Sanofi’s insulin Lantus and Amgen’s infection-fighter Neupogen in favor of…

Allergan has shown recently that it may just intend to stick to the “stepping stone deals” script it’s been talking up--at least, for now. But that hasn’t…